 |
| Pharmaceutical Industry |
Asthma is a common chronic inflammatory disease of the airways, with key symptoms being recurrent bouts of breathlessness and wheezing. The symptoms vary in severity and frequency from patient to patient. Though the exact causes of asthma are still unknown, researchers believe that host factors such as genes and environmental exposure trigger the key symptoms of the disease.
Read Full Report with TOC @ http://www.marketresearchhub.com/report/asthma-therapeutics-in-asiapacific-markets-to-2021-high-prevalence-and-launch-of-latestage-biologics-will-drive-the-market-in-spite-of-affordability-concerns-report.html
The report provides an overview of the disease, defining the epidemiology, pathophysiology, and etiology, symptoms, and diagnosis of asthma. Asthma treatment can be broadly categorized into quick-relief medication to address acute symptoms or long-control medication to treat persistent asthma. Treatment guidelines and options include Montelukast sodium as first-line maintenance therapy, inhaled corticosteroids (ICS) monotherapy for the maintenance treatment of asthma, ICS/long-acting beta-adrenoceptor agonists (LABA) combination therapy, and add-on therapies. immunomodulators, ICS, cromolyn sodium, leukotriene modifiers, methyxanthines, and nedocromil. For moderate or severe persistent asthma, LABAs can be used in combination with ICS.
The report discusses the various marketed products in the Asia Pacific asthma therapeutics market. Arnuity (fluticasone furoate) is widely available in the market as ICS for the maintenance treatment of asthma. For ICS/ LABA combination therapy, Flutiform (fluticasone propionate and formoterol fumarate) marketed by Skyepharma, Relvar/Breo (vilanterol trifenatate and fluticasone furaote), and Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) marketed by GlaxoSmithKline and Symbicort (budesonide and formoterol fumarate) marketed by AstraZeneca and co-promoted with Astellas Pharma are the commonly available drugs in this regional market. For add-on therapies or ICS/LABA combination therapy, Spiriva (tiotropium bromide), Xolair (omalizumab), and Montelukast sodium are prescribed. The report further compares the efficacy and safety of marketed products.
The report points out the key factors impacting the growth of the Asia Pacific asthma therapeutics market. The growing prevalence of asthma in the region and the introduction of alternative therapeutic choices have boosted the growth of the market. However, the usage of traditional medicines, lack of adherence to treatment regimen, limited understanding of underlying causes, and high cost of prescribed drugs will restrain the overall market growth in the coming years.
Other Related Report - http://www.marketresearchhub.com/report/asthma-therapeutics-in-asiapacific-markets-to-2021-high-prevalence-and-launch-of-latestage-biologics-will-drive-the-market-in-spite-of-affordability-concerns-report.html#related-reports
The report analyzes the growth of the Asia Pacific asthma therapeutics market across some of the key countries in the region such as China, Australia, South Korea, Japan, and India. The report further analyzes the pipeline drugs and provides information about the key co-development and licensing deals, and strategic consolidations among the key market players.
About Market Research Hub
Market Research Hub is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. MarketResearchHub’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
No comments:
Post a Comment